Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3281-3288

  Davila, Eduardo ^a   Kennedy, Richard ^a   Cells, Esteban ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOSINE; CYTOSINE GUANINE OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GUANINE; OLIGODEOXYNUCLEOTIDE; PEPTIDE DERIVATIVE; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CELL ASSAY; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MOTIF; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; THYMUS NEOPLASMS; VACCINATION; VACCINES, SUBUNIT;

EID: 0038745486     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Zinkemagel, R. M., and Doherty, P. C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol., 27: 51-177, 1979.
2. Germain, R. N., and Margulies, D. H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol., 11:403-450, 1993.
3. Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother., 50: 3-15, 2001.
4. Melief, C. J., Offringa, R., Toes, R. E.,. and Kast, W. M. Peptide based cancer vaccines. Curr. Opin. Immunol., 8: 651-657, 1996.
5. Buteau, C., Markovic, S. N., and Celis, E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin. Proc., 77: 339-349, 2002.
6. Janeway, C. A., Jr., and Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol., 20: 197-216, 2002.
7. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12: 991-1045, 1994.
8. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., and Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA, 93: 7855-7860, 1996.
9. Siegel, C. T., Schreiber, K., Meredith, S. C., Beek-Engeser, G. B., Lancki, D. W., Lazarski, C. A., Fu, Y. X., Rowley, D. A., and Schreiber, H. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J. Exp. Med., 191: 1945-1956, 2000.
10. Schoenberger, S. P., Jonges, L. E., Mooijaart, R. J., Hartgers, F., Toes, R. E., Kast, W. M., Melief, C. J., and Offringa, R. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res., 58: 3094-3100, 1998.
11. Ridge, J. P., Di Rosa, F., and Matzinger, P. A conditioned dendritic cell can be a lemporal bridge between a CD4+ T-helper and a T-killer cell. Nature (Lond.), 393: 474-478, 1998.
12. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F., and Heath, W. R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (Lond.), 393: 478-480, 1998.
13. Porgador, A., and Gilhoa, E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytoloxic T lymphocytes. J. Exp. Med., 182: 255-260, 1995.
14. Mayordomo, J. I., Zorina, T., Storkus, W. J., Celluzzi, C., Falo, L., Kasl, W. M., Ildstad, S. T., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat. Med., 1: 1297-1303, 1995.
15. Nestle, F. O., Alijagic, S. Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
16. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N. Pineiro, L., Steinman, R., and Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 61: 6451-6458, 2001.
17. Davila, E., and Celis, E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization resuits in enhanced CTL responses with anti-tumor activity. J. Immunol., 165: 539-547, 2000.
18. Grossmann, M. E., Davila, E., and Celis, E. Avoiding tolerance against prostaric antigens with subdominant peptide epitopes. J. Immunother., 24: 237-241, 2001.
19. Davila, E., Velez, M. G., Heppelmann, C. J., and Celis, E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood, 100: 2537-2545, 2002.
20. Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., El-Gamil, M., Rosenberg, S. A., and Yang, J. C. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med., 185: 453-459, 1997.
21. Schreurs, M. W., Eggert, A. A., de Boer, A. J., Vissers, J. L., van Hall, T., Offringa, R., Figdor, C. G., and Adema, G. J. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res., 60: 6995-7001, 2000.
22. Leach, D. R., Krummel, M. F., and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Wash. DC), 271: 1734-1736, 1996.
23. van Elsas, A., Hurwitz, A. A., and Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoim-mune depigmentation. J. Exp. Med., 190: 355-366, 1999.
24. Egen, J. G., Kuhns, M. S., and Allison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol., 3: 611-618, 2002.
25. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1: 751-761, 1994.
26. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett L., Schorr, J., Krieg, A. M., and Weeranta, R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol., 160: 870-876, 1998.
27. Walunas, T. L. Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., and Bluestone, J. A. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1: 405-413, 1994.
28. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoc, K. D., O'Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., and Yeo, C. J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase 1 trial of safety and immune activation. J. Clin. Oncol., 19: 145-156, 2001.
29. Dranoff, G., Jaffee, E., Lazenhy, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete routine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
30. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B. and Allison, J. P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 8099-8103, 1997.
31. van Elsas, A., Sutmuller, R. P., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J., Offringa, R., and Allison, J. P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med., 194: 481-489, 2001.
32. Hartmann, G., Weiner, G. J., and Krieg, A. M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA, 96: 9305-9310, 1999.
33. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1997.
34. Lipford, G. B., Bauer, M., Blank, C., Reiter, R., Wagner, H., and Heeg, K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol., 27: 2340-2344, 1997.
35. Krieg, A. M. CpG DNA: a novel immunomodulator. Trends Microbiol., 7: 64-65, 1999.
36. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H. Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akim, S. A Toll-like receptor recognizes bacterial DNA. Nature (Lond.), 408: 740-745, 2000.
37. Wagner, H. Toll meets bacterial CpG-DNA. Immunity, 14: 499-502, 2001.
38. Giuntoli, R. L., H. Lu, J., Kobayashi, H., Kennedy, R., and Celis, E. Direct costimulation of tumor reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin. Cancer Res., 8: 922-931, 2002.
39. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., and Riddell, S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N. Engl. J. Med., 333: 1038-1044, 1995.
40. Marzo, A. L., Kinnear, B. F., Lake, R. A., Frelinger, J. J., Collins, E. J., Robinson, B. W., and Scott, B. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol., 165: 6047-6055, 2000.
41. Topalian, S. L., Gonzales, M. I., Parhurst, M., Li, Y. F., Southwood, S., Sette, A., Rosenberg, S. A., and Robbins, P. F. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med., 183: 1965-1971, 1996.
42. Zarour, H. M., Slorkus, W. J., Brusic, V., Williams, E., and Kirkwood, J. M. NY-ESO-I encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res., 60: 4946-4952, 2000.
43. Zarour, H. M., Kirkwood, J. M. Kierstead, L. S. Herr, W., Brusic, V., Slingluff, C. L. Jr., Sidney, J. Sette, A., and Slorkus, W. J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. USA, 97: 400-405, 2000.
44. Jager, E., Jager, D., Karbach, J., Chen, Y. T. Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., Knuth, A. Identification of NY-ESO-I epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-I-expressing melanoma. J. Exp. Med., 191: 625-630, 2000.
45. Manici, S., Slumiolo, T., Imro, M. A. Hammer, J., Sinigaglia, F., Noppen, C., Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P., and Prolti, M. P. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histo-compatibility leukocyte antigen DRII. J. Exp. Med., 189: 871-876, 1999.
46. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten R., Eggermont, A. M., Boon, T., and van der Bruggen, P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med., 189: 767-778, 1999.
47. Kobayashi, H., Lu, J., and Celis, E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp 100 melanoma tumor antigen. Cancer Res., 61: 7577-7584, 2001.
48. Kobayashi, H., Song, Y., Hoon, D. S., Appella, E., and Celis, E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res., 61: 4773-4778, 2001.
49. Kobayashi, H., Wood, M., Song, Y., Appella, E., and Celis, E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res., 60: 5228-5236, 2000.